{"organizations": [], "uuid": "1791b703a9f92f40e04f450424abdd79da1e06a8", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000551/device/rss", "section_title": "California", "url": "https://www.cnbc.com/2018/05/08/the-associated-press-five-prime-therapeutics-1q-earnings-snapshot.html", "country": "US", "domain_rank": 767, "title": "Five Prime Therapeutics: 1Q Earnings Snapshot", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-09T02:09:00.000+03:00", "replies_count": 0, "uuid": "1791b703a9f92f40e04f450424abdd79da1e06a8"}, "author": "cnbc.com", "url": "https://www.cnbc.com/2018/05/08/the-associated-press-five-prime-therapeutics-1q-earnings-snapshot.html", "ord_in_thread": 0, "title": "Five Prime Therapeutics: 1Q Earnings Snapshot", "locations": [], "entities": {"persons": [], "locations": [{"name": "san francisco", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}, {"name": "south san francisco", "sentiment": "none"}], "organizations": [{"name": "prime therapeutics inc.", "sentiment": "negative"}, {"name": "ap", "sentiment": "negative"}, {"name": "zacks investment research", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "SOUTH SAN FRANCISCO, Calif. (AP) _ Five Prime Therapeutics Inc. (FPRX) on Tuesday reported a loss of $20.4 million in its first quarter.\nThe South San Francisco, California-based company said it had a loss of 63 cents per share.\nThe results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 54 cents per share.\nThe biotech company that develops treatments targeting cancer and autoimmune diseases posted revenue of $32.5 million in the period.\nFive Prime Therapeutics shares have declined 23 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $16.86, a decline of 42 percent in the last 12 months.\nThis story was generated by Automated Insights ( http://automatedinsights.com/ap ) using data from Zacks Investment Research. Access a Zacks stock report on FPRX at https://www.zacks.com/ap/FPRX", "external_links": ["https://www.zacks.com/ap/FPRX", "http://automatedinsights.com/ap"], "published": "2018-05-09T02:09:00.000+03:00", "crawled": "2018-05-09T01:29:18.011+03:00", "highlightTitle": ""}